ADL Amdl,

TUSTIN, Calif., Nov. 29 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that The Rudd Report has updated its research on AMDL, highlighting the unique opportunity AMDL has in the Chinese Pharmaceutical Market. The report said that China is developing a new and massive middle class, whose spending power will redefine the Chinese market. "These working consumers, once the country's poorest, will steadily climb the income ladder, with the result that hundreds of millions of households will enter the country's middle class. While some companies are already focusing on this evolution, many others have yet to broaden their vision and thus risk missing this extremely significant opportunity," the Rudd Report says. The estimate is that by the year 2025, urban middle class households in China will make up one of the largest consumer markets in the world. Currently people in Asia spend less than $40 per capita on pharmaceuticals, compared to $839 in the U.S. and $439 in Europe. This means that, with the middle class growing, the Asian pharmaceutical industry easily could sustain double-digit growth annually over the next decade. It is estimated that Asia's pharmaceutical market size in 2005 was approximately $106.8 billion. Antibiotics, most of which are locally manufactured generics, are the main therapeutics consumed in these developing economies. As the higher income classes expand beyond the largest urban areas into smaller cities, there will be a significant upturn in pharmaceutical sales, which will be of considerable benefit to companies such as the Jade division of AMDL, The Rudd Report says. "Given the importance of health care to Chinese families, the country's rapidly aging population, and the challenges facing the public health care system...private health expenditures by urban Chinese consumers will grow at a rate of more than 11 percent annually over the next two decades. This increase in spending will create significant opportunities for health care providers, insurance companies, medical equipment manufacturers, and pharmaceutical companies," the Report concludes. About The Rudd Report: Lauren Rudd, President of Savannah Capital Management and publisher of The Rudd Report, has more than three decades of experience in business and financial research, investment analysis and professional writing. Investment returns for his money management firm have exceeded the performance of the S&P 500 Index every year since the company's inception. Mr. Rudd's newspaper columns about Wall Street are read by an estimated six million readers daily. The paid-for research report and the update are available to be viewed at http://www.ruddreport.com/amdl_main.htm . About AMDL: AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.ruddreport.com/amdl_main.htm Web site: http://www.amdl.com/

Copyright